USPTO serial 79147297
BACHEM
Reviewed by CopyMark Law Group
Reg. 4741291Status 706Registered
- Filing date
- Status date
- Registration date
- May 26, 2015
- Examiner
- RAPPAPORT, SETH
- Law office
- POST REGISTRATION
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with BACHEM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alex R Sluzas
Alex R Sluzas Paul and PaulTwo Logan Square, 100 N. 18th St.Suite 830Philadelphia, PA 19103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in industry and science, namely, amino acids, peptides, reagents for peptide synthesis, amino acid derivatives, cytokines, enzyme inhibitors, enzyme substrates, growth factors, peptide substrates, all for use as scientific and laboratory research reagents in the field of medicine and molecular biology; pharmaceutical intermediates for use in the further manufacture of pharmaceuticals; chemical products used for preserving foodstuffs | ACTIVE | — |
| 005 | Pharmaceutical and veterinary products, namely, pharmaceutical preparations for use in the treatment of bleeding, premature labor, pulmonary hypertension, erectile disfunction, coronary syndromes, prostate cancer, endometriosis, central precocious puberty, uterine myoma, osteoporosis, hypercalcernia, Paget's disease, reflex sympathetic dystrophy, nocturnal enureses, central diabetes insipidus, polyuria, polydipsia, hemophilia A, von Willebrand disease, unstable angina, myocardial infarction, hypoglycemia, ovarian follicular cysts, cryptochism, breast cancer, growth hormone deficiency, acromegaly, carcinoid syndrome, thyrotrophic adenomas, diabetes II, VIPosmas, ulcer bleeding, hemorrhagic gastritis, postoperative pancreatic and duodenal fistulae, variceal hemorrhage, neurological diseases, rheumatic diseases, skin diseases, diseases of the intestinal tract, cancer, conjunctivitis, glaucoma, ocular hypertension, Parkinson's disease, transfusion-induced hemosiderosis, candidasis, dermatophytosis, pityriasis, congenital homocystinuria, hyperammonaemia, hepatic encephalopathy, ischemic heart disease, chorioretinal vascular disorders, hypertension, endema, insomnia, bipolar disorder, and schizophrenia; pharmaceutical preparations for use in the diagnosis of gastrinoma; veterinary preparations for use in the induction of ovulation in estrous mares, and reproduction control in dogs and cats; pharmaceutical preparations for use in the diagnosis of Cushing's syndrome, hypothalamic-pituitary-gonadal axis function, growth hormone deficiency, pancreatic exocrine dysfunction, gastrinoma, and adrenocortical insufficiency; dietetic food and substances for medical or veterinary use, namely, taste-modulating food additives in the nature of peptides for medical use, appetite suppressors for medical use; food supplements for humans and animals; fungicides; herbicides | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 4, 2026 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Sep 4, 2026 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Jun 15, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jan 12, 2026 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Nov 30, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 12, 2025 | PUMI | PROOF OF USE INTERIM ACTION ISSUED | — |
| Jun 10, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jun 4, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| May 23, 2025 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Jun 25, 2024 | PUM1 | OFFICE ACTION ISSUED POU1 | — |
| Jun 25, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jun 18, 2024 | ES71 | TEAS SECTION 71 RECEIVED | — |
| May 26, 2024 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Apr 18, 2024 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Mar 22, 2021 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Mar 22, 2021 | C75A | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Mar 22, 2021 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Feb 18, 2021 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| May 26, 2020 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Feb 1, 2019 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 30, 2015 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 24, 2015 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 24, 2015 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 26, 2015 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 26, 2015 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 10, 2015 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 10, 2015 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 6, 2015 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 18, 2015 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 18, 2015 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 18, 2015 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 30, 2015 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jan 29, 2015 | ALIE | ASSIGNED TO LIE | — |
| Jan 9, 2015 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 9, 2015 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 9, 2015 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 9, 2015 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 9, 2015 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 8, 2015 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 8, 2015 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 8, 2015 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 8, 2014 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 23, 2014 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 23, 2014 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 18, 2014 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 17, 2014 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 17, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 3, 2014 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 30, 2014 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 29, 2014 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |